Moderna, Inc. (MRNA): A Bull Case Theory
We came across a bullish thesis on Moderna, Inc. (MRNA) on Natan’s Substack. In this article, we will summarize the bulls’ thesis on MRNA. Moderna, Inc.
Moderna Inc. (MRNA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Theleme Partners Patrick Degorce | 7,242,390 | $205,321,756 | -1% | 16.14% |
| 2. | D E Shaw D. E. Shaw | 5,636,151 | $159,784,881 | +219% | 0.14% |
| 3. | 4,895,300 | $138,781,755 | +44% | 0.03% | |
| 4. | 3,931,400 | $111,455,190 | +15% | 0.02% | |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 3,808,500 | $107,970,975 | +3573% | 0.24% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.53 | 57,493 | $1,812,754.29 | 9,210,686 | 2025-03-03 | Filing | |
| $31.04 | 102,821 | $3,191,563.84 | 9,153,193 | 2025-03-03 | Filing | |
| $31.76 | 31,620 | $1,004,251.20 | 312,027 | 2025-03-03 | Filing | |
| $19.00 | 52,631 | $999,989.00 | 420,407 | 2020-02-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $28.00 | 312 | $8,736.00 | 580 | 2025-06-11 | Filing | |
| $44.68 | 529 | $23,637.31 | 20,446 | 2024-12-09 | Filing | |
| $43.30 | 112 | $4,849.28 | 19,837 | 2024-12-03 | Filing | |
| $43.30 | 314 | $13,595.29 | 1,443,904 | 2024-12-03 | Filing | |
| $42.79 | 1,420 | $60,760.52 | 11,066 | 2024-11-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 40,396,513 | $1,145,241,144 | 0.02% | |
| 2. | 27,181,154 | $770,585,733 | 0.02% | |
| 3. | 24,948,558 | $707,291,620 | 0.62% | |
| 4. | 21,130,029 | $599,036,329 | 0.04% | |
| 5. | 17,778,558 | $504,022,119 | 0.02% |
News See All
Moderna RSV Vaccine Gains Expanded FDA Approval for Younger Adults
Moderna Inc. (NASDAQ:MRNA) is one of the best mid cap growth stocks to invest in now.
11 Best Mid Cap Growth Stocks To Invest In Now
On June 18, Scott Wren, Wells Fargo senior global market strategist, joined CNBC's 'Closing Bell Overtime' to talk about how the market sell-off is an opportunity to step in.
Moderna (MRNA) Faces Multiple Regulatory Challenges
On May 31, Bloomberg reported that the FDA recently granted Moderna Inc. (NASDAQ:MRNA) a narrower approval for its next-generation COVID-19 vaccine.
Jim Cramer on Moderna (MRNA): “I’ve Been Against This Stock For So Long”
We recently published a list of Jim Cramer Talked About These 13 Stocks. In this article, we are going to take a look at where Moderna, Inc.
Jim Cramer Talked About These 13 Stocks
“If you want to know what makes a successful retailer, all you have to do is read the conference calls. Everything's on display, no secret sauces. I'm always telling you to read these transcripts.
Moderna, Inc. (MRNA) Submits Updated COVID Vaccine for Regulatory Review
The revised version of the vaccine, marketed as Spikevax, follows FDA guidance recommending that this year’s shots target variants from the JN.1 lineage, specifically favoring the LP.8.1 strain.
Why Moderna, Inc. (MRNA) Crashed Today
We recently published a list of 10 Firms Drenched in Red Today.